Data / Drug companies / Amneal Pharmaceuticals Co. (i) Pvt. Ltd.
Amneal Pharmaceuticals Co. (i) Pvt. Ltd.: 11 products in the FDA NDC directory, labeler code 52493
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Amneal Pharmaceuticals Co. (i) Pvt. Ltd. (labeler code 52493) lists 11 products in the FDA National Drug Code Directory. By type: 9 bulk ingredients, 2 drugs for further processing. Its main marketing category is bulk ingredients. The newest product started marketing on July 20, 2024.
The request: Watch Amneal Pharmaceuticals Co. (i) Pvt. Ltd. (FDA labeler code 52493): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 52493
- Products in commercial distribution
- 11
- Packages
- 11
- Finished drugs by generic name
- 0
- Prescription products
- 0
- Over the counter products
- 0
- Started marketing in the last 12 months
- 0
- Earliest marketing start
- June 27, 2013
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Bulk ingredients | 9 | 81.8% |
| Drugs for further processing | 2 | 18.2% |
Products by type
| Type | Products | Share |
|---|---|---|
| Bulk ingredients | 9 | 81.8% |
| Drugs for further processing | 2 | 18.2% |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Granule | 5 | 45.5% |
| Tablet, extended release | 4 | 36.4% |
| Powder | 1 | 9.1% |
| Tablet | 1 | 9.1% |
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Telmisartan | 52493-903 | Granule | Bulk ingredients | July 20, 2024 |
| Guaifenesin and dextromethorphan hbr | 52493-039 | Tablet, extended release | Drugs for further processing | July 3, 2024 |
| Guaifenesin and dextromethorphan hbr | 52493-038 | Tablet, extended release | Drugs for further processing | July 3, 2024 |
| Guaifenesin | 52493-037 | Tablet, extended release | Bulk ingredients | April 10, 2024 |
| Guaifenesin | 52493-036 | Tablet, extended release | Bulk ingredients | April 10, 2024 |
| Entecavir | 52493-449 | Granule | Bulk ingredients | September 20, 2023 |
| Entecavir | 52493-446 | Granule | Bulk ingredients | September 20, 2023 |
| Cetirizine hydrochloride | 52493-046 | Tablet | Bulk ingredients | July 20, 2022 |
| Etravirine | 52493-200 | Granule | Bulk ingredients | January 25, 2022 |
| Tadalafil common blend | 52493-150 | Granule | Bulk ingredients | September 24, 2020 |
| Metformin | 52493-334 | Powder | Bulk ingredients | June 27, 2013 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.